Novel Topical CRISPR-based Therapy May Help Treat EB, Eczema, and Psoriasis

A topical gene-editing-based therapy may offer a lasting cure for a range of skin disorders.

Outlined recently in a paper published in Cell Stem Cell, the findings could lead to new treatments for a wide range of genetic skin conditions, from rare inherited diseases to more common disorders like eczema.

“With this work, we show that it is possible to correct disease-causing mutations in human skin using a topical treatment that is safe, scalable and easy-to-use,” says Dr. Sarah Hedtrich, an Associate Professor at University of British Columbia’s (UBC) School of Biomedical Engineering in Vancouver, BC, and Senior Author of the study. “Importantly, the approach corrects the root cause of disease, and our data suggests that a one-time treatment might even be enough to provide a lasting and durable cure.” UBC researchers from partnered with colleagues from the Berlin Institute of Health at Charité in Germany.

In the study, the researchers show the gene therapy can correct the most common genetic mutation behind autosomal recessive congenital ichthyosis (ARCI).

By testing the treatment in models made from living human skin, the team showed it can restore up to 30% of normal skin function—a level that previous research suggests could be clinically meaningful for returning skin function to normal.

While ARCI affects relatively few people, the researchers say the treatment strategy could be adapted to many other genetic skin diseases, including epidermolysis bullosa and potentially more common conditions such as eczema or psoriasis.

“The approach we developed is a platform technology,” says Dr. Hedtrich. “It can be readily adapted to treat almost any skin disease.”

Despite major advances in gene editing, applying the technology to skin diseases has remained a long-standing challenge. To overcome this, the team developed a novel delivery method that uses lipid nanoparticle technology, or LNPs.

Using a clinically approved laser, the researchers first create microscopic, pain-free openings in the outer layers of the skin. This allows the lipid nanoparticles to pass through the skin barrier and reach skin stem cells beneath the surface. Once inside, the gene editor corrects the underlying DNA mutation, enabling the skin to begin functioning more normally.

“This is a highly targeted, localized approach,” says Dr. Hedtrich. “The treatment stays in the skin, and we saw no evidence of off-target effects, which is a critical safety milestone.”

The study was conducted in collaboration with Vancouver-based biotech company NanoVation Therapeutics, a UBC spin-off focused on developing LNP-based genetic medicines. The researchers now hope to bring the treatment into clinical testing and have already been working with regulatory authorities to define the necessary safety and efficacy studies.

“Our goal now is to take this from the lab into first-in-human clinical trials,” adds Dr. Hedtrich. “We hope this work will ultimately lead to a safe, effective treatment that can transform the lives of patients who currently have no real therapeutic options.”